DexCom, Inc. (DXCM) Expected to Post Quarterly Sales of $217.84 Million

Wall Street brokerages expect DexCom, Inc. (NASDAQ:DXCM) to announce sales of $217.84 million for the current quarter, Zacks reports. Six analysts have issued estimates for DexCom’s earnings, with the lowest sales estimate coming in at $217.50 million and the highest estimate coming in at $218.16 million. DexCom posted sales of $171.20 million during the same quarter last year, which suggests a positive year over year growth rate of 27.2%. The business is expected to report its next earnings report after the market closes on Tuesday, February 27th.

On average, analysts expect that DexCom will report full-year sales of $217.84 million for the current financial year, with estimates ranging from $715.00 million to $725.00 million. For the next year, analysts expect that the company will post sales of $840.16 million per share, with estimates ranging from $833.80 million to $847.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow DexCom.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. The firm had revenue of $184.60 million for the quarter, compared to analyst estimates of $183.42 million.

A number of brokerages have commented on DXCM. TheStreet lowered shares of DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. BidaskClub lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. ValuEngine raised shares of DexCom from a “sell” rating to a “hold” rating in a research note on Monday, November 6th. Morgan Stanley reduced their target price on shares of DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company’s stock. DexCom currently has a consensus rating of “Buy” and an average price target of $68.50.

In other DexCom news, Director Steven R. Altman purchased 10,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was bought at an average cost of $49.61 per share, with a total value of $496,100.00. Following the purchase, the director now directly owns 4,353 shares of the company’s stock, valued at $215,952.33. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Barbara Kahn sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $54.58, for a total transaction of $163,740.00. Following the transaction, the director now directly owns 4,353 shares of the company’s stock, valued at $237,586.74. The disclosure for this sale can be found here. Insiders have sold a total of 48,140 shares of company stock worth $2,743,281 over the last 90 days. Corporate insiders own 1.70% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Advisor Group Inc. grew its stake in shares of DexCom by 104.9% during the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after acquiring an additional 837 shares in the last quarter. Zions Bancorporation grew its stake in shares of DexCom by 36,222.2% during the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after acquiring an additional 3,260 shares in the last quarter. Toronto Dominion Bank grew its stake in shares of DexCom by 251.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after acquiring an additional 2,608 shares in the last quarter. First Manhattan Co. bought a new position in shares of DexCom during the 4th quarter worth approximately $223,000. Finally, CAPROCK Group Inc. bought a new position in shares of DexCom during the 4th quarter worth approximately $224,000.

Shares of DexCom (NASDAQ DXCM) opened at $57.87 on Friday. DexCom has a fifty-two week low of $42.62 and a fifty-two week high of $86.32. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84. The company has a market cap of $5,057.76 and a PE ratio of -101.52.

ILLEGAL ACTIVITY WARNING: “DexCom, Inc. (DXCM) Expected to Post Quarterly Sales of $217.84 Million” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/02/dexcom-inc-dxcm-expected-to-post-quarterly-sales-of-217-84-million.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply